Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. by Saper, Joel R et al.
UCSF
UC San Francisco Previously Published Works
Title
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: 
ONSTIM feasibility study.
Permalink
https://escholarship.org/uc/item/45c3t59d
Journal
Cephalalgia : an international journal of headache, 31(3)
ISSN
0333-1024
Authors
Saper, Joel R
Dodick, David W
Silberstein, Stephen D
et al.
Publication Date
2011-02-01
DOI
10.1177/0333102410381142
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Original Article
Occipital nerve stimulation for the
treatment of intractable chronic migraine
headache: ONSTIM feasibility study
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Sally McCarville4, Mark Sun4 and Peter J Goadsby5 for the
ONSTIM Investigators
Abstract
Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache 15 days per
month.
Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and
efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and
responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM)
groups.
Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66.
A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month
or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder
rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration
occurred in 12 of 51 (24%) subjects.
Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS
in CM.
Keywords
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Introduction
Migraine is ranked by the World Health Organization
as among the world’s most disabling medical conditions
(1), affecting 12% of the US population: 18% of
women and 6% of men (2). During the course of
their illness, which often begins in childhood or adoles-
cence, approximately 3% to 14% of migraine patients
will progress to chronic migraine (CM), with more than
half of the days of each month in pain (3). Despite
major advances in understanding the pathogenesis of
migraine, new pharmacologic treatments (4) and the
availability of intensive systems of care for difficult
cases, in many patients migraines remain intractable
to medical therapy (5).
In 1999 Weiner and Reed reported the beneficial
effects of subcutaneous occipital nerve stimulation
(ONS) in 12 of 13 patients who they believed to have
occipital neuralgia (6). Leads were placed in the subcu-
taneous tissue superficial to the cervical musculature and
fascia transversing the occipital nerves at the level of C1.
A review of Weiner’s cases by author JRS at the behest
of Medtronic Neuromodulation resulted in a challenge
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to the diagnosis of occipital neuralgia (unpublished
results). JRS subsequently recommended that these
patients be evaluated by author PJG using functional
neuroimaging (positron emission tomography). These
studies, performed in eight patients, demonstrated
brain changes (phenotype and imaging signature) con-
sistent with CM (7).
Published reports from open-label studies have dem-
onstrated possible efficacy of ONS in a variety of pri-
mary headache disorders, including CM (8,9), cluster
headache (10), occipital neuralgia (11) and hemicrania
continua (12). These findings, those of Weiner and
Reed (6) and those of Goadsby and colleagues (7)
prompted the development of a feasibility study. The
goals of the trial were to determine whether a well-
designed, controlled study that included a valid placebo
arm could demonstrate insights into the potential ben-
efits and risks of this new therapy. Among the potential
risks to be assessed were lead migration, lead fracture,
skin erosion, infection, loss of effect, muscle spasm and
battery malfunction or depletion. Preliminary results
have been presented (American Headache Society
Annual Scientific Meeting, Boston, MA, June 26,
2008; European Headache and Migraine Trust
International Congress, September 2008; and
American Academy of Neurology, Seattle, WA, April
2009) (13,14).
Methods
The study was prospective, multicenter, randomized,
blinded, and placebo-controlled. It was designed to
obtain preliminary safety and efficacy data for ONS
treatment of CM. As a feasibility study, especially in
a patient population that has been the focus of very few
randomized controlled trials, no primary endpoint was
prespecified; rather, a range of efficacy measures was
identified and evaluated at three months in comparison
to baseline. Among the endpoints measured were
reduction in headache days per month, decrease in
overall pain intensity (0–10 scale) and responder rate
(i.e. percentage of patients with a 50% drop in head-
ache days per month or a 3-point drop in overall pain
intensity from baseline, based on daily electronic diary
data). A headache day was defined as each day that a
subject rated his or her overall headache pain intensity
as 3. CM was diagnosed using the second edition of
the International Classification of Headache Disorders
(ICHD-II) (15). Subject enrollment criteria included (i)
headaches occurring on 15 or more days per month for
more than three months in the absence of medication
overuse, (ii) pain involving the occipital or suboccipital
region and (iii) pain refractory to preventive medica-
tions. Key inclusion and exclusion criteria are listed in
Table 1.
Study groups
Subjects who met enrollment criteria were then random-
ized into one of three treatment groups, adjustable stim-
ulation (AS), preset stimulation (PS) and medical
management (MM), using a randomization ratio of
2:1:1, respectively. After implantation, the AS group
was instructed to maintain the stimulator in the ‘‘on’’
position and to adjust the device to minimize pain.
Serving as the control group for the AS group were sub-
jects who received an implanted device that provided PS
rather than AS. For these patients the device was set at a
stimulation setting for one minute each day during the
blinded phase of the study. A third group, also serving as
a control group, received only MM during the blinded
phase of the study. Unlike subjects in the AS and PS
groups, who were required to maintain stable medica-
tion regimens (although frequency and dose of acute
medications could change if necessary), subjects in the
MM group were able to adjust, change and optimize
medication regimens as directed by their physicians. A
fourth group, the ancillary group, met all entry criteria
except response to occipital nerve block (ONB), which
was an entry criterion for the other groups. A lack of
response to ONB was defined as a failure to experience
at least a 50% reduction in migraine pain within 24
hours of the injection of 3–5ml of 0.5% bupivacaine
into each greater occipital nerve distribution. Patients
in the ancillary group were implanted and allowed to
adjust the stimulation and were treated identically to
the AS group. Figure 1 illustrates the randomization
and study design scheme.
Sites and blinding
The evaluation was conducted at seven centers in the
US, one center in Canada, and one in the UK. The
distributions of enrollment and treatment assignments
by investigational center are shown in Table 2. A neu-
rologist (headache specialist) was first identified at each
center as the principal investigator except at two cen-
ters, where an implanter, usually an anesthesiologist,
was first identified as the principal investigator. All
headache specialists were blinded to the subjects’
group assignments and were responsible for establish-
ing the diagnosis, optimizing subjects’ medications and
evaluating subjects’ headaches at follow-up visits. None
of the implanters were blinded to the subjects’ group
assignments, and all were responsible for follow-up
with subjects on device implantation, device activation
and programming.
After confirmation of eligibility by the headache spe-
cialists, subjects were randomized into three treatment
groups. Randomization was balanced across all centers
but not within each center due to the anticipated
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Table 1. Inclusion and exclusion criteria
Inclusion  Diagnosis of CM headache as defined by the 2004 IHS criteria:
 Migraine headache occurring on 15 or more days/month for more than three months in absence of medication
overuse.
 Not attributed to another disorder.
 Headache pain defined by the following criteria:
 During each of two consecutive periods of four consecutive weeks, a minimum of 15 days of CM headache with
peak pain intensity 5 (on a 0–10 scale).
 Subject may have headache of any intensity (0–10 scale) on days over 15 during each four-week period.
 Headache pattern has been present for 12 months or longer.
 Refractory, as determined by failure to respond or intolerance to an adequate trial of preventative medications from
at least two different classes of drugs.
 Headache is characterized by:
 Pain located between C3 level to vertex.
 Any location between ears (i.e. occipital or suboccipital region within distribution of greater and/or lesser occipital
nerves).
 Pain may be unilateral or bilateral and may include pain in frontal, temporal or retro-orbital region or into neck/
shoulder location.
 Onset of migraine headache occurred before age 50 years.
 Current acute and prophylactic headache medication regimens have been stabilized for four weeks prior to preliminary
enrollment visit.
 Response to a temporary, short-acting anesthetic block to the occipital distribution was positive.
 Subject is age 18 years or older and has signed informed consent form.
 Subject will be available for appropriate follow-up for the duration of study and is willing and able to maintain current
medication regimens during enrollment process and through three-month follow-up visit.
 In physician’s opinion, subject is willing and able to use electronic daily questionnaire equipment.
 Female subject of childbearing potential has negative pregnancy test at confirmation of enrollment visit, is not nursing
and agrees to use adequate birth control methods for duration of study.
Exclusion  In physician’s opinion subject has health conditions or concerns that would render them unable to participate, would
impact ability of subject to adequately assess incremental effects of ONS treatment, could possibly be aggravated by
treatment or confound ability to interpret results (including, but not limited to, intractable epilepsy, active major
depression, psychosis, somatoform disorder, severe personality disorder). Other conditions to be considered include
cardiac arrhythmias, cognitive impairment and peripheral neuropathy.
 Previous destructive ganglionectomy, rhizotomy section or neurectomy procedure affecting C2/C3/occipital
distribution.
 Subject is not candidate for or is not willing to undergo surgical implantation of neurostimulator system.
 Subject is deemed by investigator to have rebound headaches, and/or subject reports regular use on three or more
days per week of acute medication that can cause rebound headaches.
 Subject has participated in:
 Three clinical trials for headache, in last five years or
 Previously terminated from this clinical trial or
 Another neurological device or drug trial within last 90 days.
 Subject has other implanted electrical stimulation device(s) or any metallic implant or is expected to require an implant,
including:
 Cardiac demand pacemakers or defibrillators
 Cochlear implant
 CSF shunt
 Aneurysm clip
 Spinal cord stimulator
 Neurostimulation (implanted or external) for headache or other head or neck pain was received within last year.
 Significant psychological signs on examination and/or history, or has serious drug habituation or behavioral problems
that in physician’s judgment renders that person inappropriate for study.
 Unresolved legal issues related to their pain that is being assessed in this study.
 Failure to complete at least 23 out of 28 days, during two consecutive 28-day periods, of electronic daily questionnaire
during enrollment process.
 Alternative therapy to treat headache pain (e.g. massage, biofeedback, bracing) is being used or will be used.
 MRI or diathermy may be required.
 Other medical or neurological conditions that would confound study.
CM¼ chronic migraine. IHS¼ International Headache Society. ONS¼ occipital nerve stimulation. CSF¼ cerebrospinal fluid. MRI¼magnetic reso-
nance imaging.
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relatively small number of subjects per center. The
randomization was not stratified for baseline charac-
teristics. A central randomization process provided
and managed by Medtronic Neuromodulation
(Medtronic) assigned a unique randomization code to
each subject. Initially, randomization revealed only
whether a subject was assigned to ‘‘medically managed’’
or ‘‘device implanted.’’ To maintain blinding in the
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Figure 1. Randomization and study design, three-month overview. Adjustable stim¼ adjustable stimulation group. Preset
stim¼ preset stimulation group.
Table 2. Distribution of enrollment and subjects analyzed by investigational center
Investigational center
Subjects
enrolled
Assigned to
treatment group
In 3-month
analysis
UK — National Hospital for Neurology and Neurosurgery 18 12 12
US — North County Neurology Associates 17 11 11
Canada – Foothills Medical Centre 13 10 10
US — Jefferson Headache Center at Thomas Jefferson University 13 10 6
US — Mayo Clinic (Scottsdale) 11 9 9
US — Henry Ford Hospital 11 7 7
US — Oklahoma University Physicians – Pain Medicine 11 6 2
US — Michigan Head-Pain and Neurological Institute 9 7 6
US — University of Colorado Health Sciences Center 7 3 3
Total 110 75 66
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device-implanted group, a sealed envelope with the
complete randomization assignment (level of stimula-
tion) was sent to implanter site personnel by Medtronic
to be opened at the activation visit. Subjects were
blinded to the anticipated value of adjustable stimula-
tion over that of the preset stimulation. The sponsor’s
study personnel (Medtronic) were not blinded to the
randomized treatment assignments for individual
subjects.
Device
The study was conducted using the Medtronic model
7427 Synergy and model 7427V Synergy Versitrel
implantable pulse generators, model 3487A Pisces
Quad and model 3887 Pisces Quad-Compact leads,
model 7489 and model 7482 extensions, model 3550-
25 accessory kit, model 3655-60 tunneling tool kit,
model 8840 clinician programmer, model 8870 applica-
tion card, model 3628 dual-screen test stimulator and
model 7435 Synergy EZ patient programmer. The
product specifications of stimulation parameters for
both models of implantable pulse generator are the
same and as follows:
. Pulse amplitude: 0–10.5V
. Pulse rate: 3–130Hz
. Pulse width: 60–450 ms
Study procedures
Entry to study. After approval of regulatory agencies,
institutional review boards or ethics committees, sub-
jects who provided written informed consent and met
eligibility criteria were enrolled to the study. The enroll-
ment process had three steps: preliminary enrollment
visit, daily questionnaire enrollment phase and confir-
mation of enrollment visit. At the preliminary enroll-
ment visit, information was collected, including health
and well-being status, medical history and medication
history. A preliminary diagnosis was also rendered.
During the daily questionnaire enrollment phase, sub-
jects completed an electronic daily questionnaire
(EDQ) for a minimum of nine weeks, providing infor-
mation about their headache, daily functional ability
and medications taken. During the first week, subjects
familiarized themselves with the questionnaire equip-
ment. The purpose of the last eight weeks before the
confirmation of enrollment visit was to establish base-
line headache data. During the confirmation of enroll-
ment visit, data from the EDQ was evaluated for diary
compliance and headache features. Subjects who con-
tinued to meet eligibility requirements were given a
short-acting ONB by the neurologist investigator.
Those with a positive response to the ONB were eligible
for randomization to the study. The first eight sub-
jects study-wide who did not respond to ONB were
entered into the ancillary group. Subjects who did not
complete the enrollment process, did not respond to
ONB (after the ancillary group was filled) or who did
not wish to continue had no further participation in
the study.
Implantation. Using local anesthesia and fluoro-
scopic guidance, one or two leads were implanted sub-
cutaneously, superficial to the fascia and muscle layer
at the level of C1. Intraoperative testing was consis-
tently performed according to the ONS System
Manual to determine if a subject’s response to stimula-
tion, as judged by adequate paresthesia coverage of the
area of headache pain, was appropriate to receive a full
implant. There was no trial of stimulation treatment. If
during intraoperative testing the implanter believed
inadequate paresthesia occurred over the location of
pain based on the patient’s responses, the leads were
removed, and the subject was followed for 30 days for
safety and then terminated from the study. Subjects
who felt adequate paresthesia over the target pain loca-
tion during intraoperative testing continued with the
implant procedure. Final lead placement was identified
by X-ray. The implant procedure was performed with
additional intravenous sedation to reduce patient dis-
comfort; after lead placement was determined, the lead
was locked in place using the twist connector, and a
winged anchor was sutured in place. Connectors and
extensions were used to allow placement of the neuro-
stimulator just under the skin in the abdomen to reduce
lead migration; if the abdominal site was determined to
be inappropriate by the physician, the buttock was
used. To further reduce the incidence of lead migration,
the lead extension was placed with circular coils, creat-
ing strain-relief loops. Not all of these implant tech-
niques, such as use of strain-relief loop, were
employed consistently at the beginning of or during
the study. However, a recommendation of using
strain-relief loop and preference of abdominal to but-
tock implant location of the neurostimulator was pro-
vided to all implanters during the study when a number
of lead migrations were reported.
The device was activated after the surgical site healed,
between 7 and 14 days after implantation. All subjects
received ONS using parameters optimized by the physi-
cian on the basis of their response to treatment, but the
duration of stimulation differed according to group
assignment. Patients in the PS group received one
minute per day of stimulation and were instructed that
their neurostimulator had been pre-programmed to deli-
ver the correct amount of stimulation as determined by
their treating physician. Patients in both the AS and PS
groups were not informed of the predicted effectiveness
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of their treatment. Patients in the AS and ancillary
groups received a device programmer allowing them to
turn the neurostimulator on and off and to make minor
adjustments to settings, and they were instructed to
maintain the stimulator in the ‘‘on’’ position as much
as possible. Subjects in the PS group were not given a
device programmer to adjust the settings.
Follow-up visits. All enrolled subjects had follow-up
visits at one and three months. Safety and efficacy were
evaluated at the three-month visit. Subjects in the PS
and MM (control) groups were offered adjustable ONS
therapy after the three-month follow-up visit. Subjects
in the ancillary group were treated in the same manner
as AS subjects and followed the same visit schedule.
Subjects in the AS, PS and AG groups who were on
medications were required to maintain stable medicine
regimens, although the frequency and dose of acute
medications could change if necessary. Those in the
MM group were able to adjust and change medication
regimens throughout the three-month blinded phase, as
directed by their physicians. After the three-month
follow-up visit, all subjects, regardless of initial group,
were able to adjust acute and prophylactic medication
regimens as needed.
The ONSTIM feasibility study has completed three-
month blinded follow-up visits for safety and efficacy
endpoints. Subsequent open-label, long-term follow-up
visits included 6, 12, 24, and 36 months. Not all of these
long-term follow-up visits have been completed at the
time of this manuscript; hence, only three-month safety
and efficacy results are reported here.
Safety
The three-month safety objectives were evaluated by
determining adverse device-related events (ADEs) for
all implanted subjects, including ADEs reported
during intraoperative testing and scheduled and
unscheduled visits throughout the three-month follow-
up period. ADEs were classified into those related to
the components of the system, the implant procedure,
device programming or device stimulation.
Non–device-related adverse events also were
collected for all subjects at scheduled and unscheduled
visits beginning with the confirmation of enrollment
visit and throughout the three-month follow-up
period. They were classified using the MedDRA
Version 8.0 dictionary and the Medtronic
Neuromodulation Device Event Dictionary.
Per protocol, there was no data safety monitoring
board (DSMB) or clinical events committee (CEC)
for this feasibility study. All adverse events regardless
of device relatedness were reviewed and monitored by
the Medtronic Neuromodulation medical advisor
throughout the study. A serious unanticipated ADE
or a percentage of subjects experiencing a specific
serious ADE higher than previously reported were
defined as criteria for consideration of modification or
termination of the study.
Data collection
Data were collected using electronic diary for headache
days, pain and duration measurements. Paper case
report forms were used for data collection of safety
and quality of life. Data collected for safety objectives
included device-related and non–device-related adverse
events; data collected for efficacy objectives included
headache days, headache-free days, days with pro-
longed and severe headache, headache pain intensity,
headache duration, responder to ONS therapy, func-
tional impairment (functional disability scale), migraine
disability assessment (MIDAS), quality of life (SF-36)
and subject satisfaction.
Analytic considerations
The sample size was chosen to gain experience with
ONS therapy for the treatment of CM. In order to
evaluate effectively the study design, a sample size of
24 subjects in the AS group and 12 subjects in each of
the PS and MM groups was required. In keeping with
the exploratory nature of the study, it was not powered
for a single primary endpoint. However, according to
the protocol, statistical analysis was performed to allow
more critical consideration of the data in order to iden-
tify factors and nuances that might be helpful in further
studies. A per-protocol analysis, including all subjects
who completed the electronic diary during the three-
month blinded follow-up, was used to compare subjects
who completed three months of stimulation therapy in
the AS group with subjects in the PS, MM and ancillary
groups who also completed three months of follow-up.
Pairwise comparisons between the AS group and each
of the three other groups were not adjusted for multiple
comparisons and are presented only as a guide to inter-
preting the study. We considered differences with
p< .05 as potentially informative, and these are nomi-
nally referred to as statistically significant throughout
the paper, with actual p values not reported due to the
exploratory nature of the analyses. Wilcoxon’s rank
sum tests were used to analyze headache days, pain
intensity, disability and quality-of-life outcomes; these
summary data are presented as mean standard devi-
ation. Fisher’s exact tests were used to analyze respon-
der rate and subject satisfaction; these summary data
are presented as frequency counts and percentages. For
the safety objective of the study, descriptive summaries
are presented. SAS software (version 9.1, SAS Institute,
Cary, NC, USA) was used for all data analyses.
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An interim analysis was conducted in January 2007
for business planning of future studies. No stopping
rules were applied because the analysis was unrelated
to safety, which is monitored and evaluated on an
ongoing basis as described above. The results of this
interim analysis were not provided to the investigators.
Results
The clinical investigation began on May 26, 2004, and
the last subject was enrolled on April 6, 2007. The final
three-month follow-up visit was conducted on
November 13, 2007. A total of 110 subjects aged 18
years and older were enrolled to achieve the final
sample size of 75 subjects assigned to a treatment
group (Figure 2). Thirty-five subjects discontinued the
study prior to being assigned to a treatment group. The
most common reasons for discontinuation were failure
to meet the confirmation of enrollment criteria, with-
drawal of consent or physician-determined withdrawal
prior to treatment assignment. After meeting the study
inclusion criteria, subjects were randomized into the
study groups: 33 subjects in the AS group; 17 subjects
in the PS group; and 17 subjects in the MM control
group (ratio 2:1:1, respectively). Eight subjects were
entered into the ancillary group to evaluate the predic-
tive value of ONB. Of the 75 subjects assigned to a
treatment group, eight discontinued prior to the end
of the three-month blinded phase of the study: four
subjects withdrew consent prior to implant (two AS,
one PS, 1 ancillary group); two subjects were intrao-
perative failures (one AS, one ancillary group); one AS
subject was lost to follow-up prior to implant; one
ancillary group subject discontinued after the one-
month follow-up visit because of lack of efficacy. Of
the 67 subjects who continued to the three-month
blinded follow-up, one subject (AS) did not complete
the EDQ between implant and three months; 66 sub-
jects (28 AS, 16 PS, 17 MM, 5 ancillary group)
completed the EDQ through the three-month follow-up
period.
The subjects experienced migraine for an average of
22.0 years prior to the study (range, 1–51 years) and
experienced CM headaches for an average of 10.0 years
prior to study enrollment (range, <1–30 years). The
gender ratio of males to females was approximately
1:4. Treatment groups were similar in demographic
and baseline headache characteristics (Table 3).
Changes in headache days, pain, and duration
The overall outcomes comparing baseline observations
and three-month data are presented in Table 4. At three
months, percent reduction in headache days per month
was 27.0 44.8% for AS, 8.8 28.6% for PS,
4.4 19.1% for MM and 39.9 51.0% for the ancillary
group. These percentages correspond to reductions in
actual headache days per month of 6.7 10.0 for AS,
1.5 4.6 for PS, 1.0 4.2 for MM and 9.1 12.3 for
the ancillary group. The reduction in overall pain inten-
sity was 1.5 1.6, 0.5 1.3, 0.6 1.0 and 1.9 3.5 for
AS, PS, MM and the ancillary group, respectively. The
percent reduction in days with prolonged, severe head-
ache per month was 24.4 43.6% for AS, 10.3 34.0%
Enrolled: 110
Discontinued: 35
Medically managed:
Randomized: 17
3-month: 17
Preset stim:
Randomized: 17
Implanted: 16
3-month: 16
Adjustable stim:
Randomized: 33
Implanted: 29
3-month: 29
Assigned to 
treatment
group: 75
Ancillary group:
Assigned: 8
Implanted: 6
3-month: 5
Figure 2. Disposition of patients in the study. Adjustable stim¼ adjustable stimulation group. Preset stim¼ preset stimulation group.
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for PS, 1.2 38.9% for MM and 33.5 43.2% for the
ancillary group. These percentages correspond to
reduction in actual days per month of 5.1 8.7 for
AS, 2.2 6.4 for PS, 0.8 5.6 for MM and 7.7 11.7
for the ancillary group. Figures 3 through 6 show the
percentage change in number of headache days per
month, change in overall pain intensity, percentage
change in number of days with prolonged, severe head-
ache and change in hours of headache per day across all
four groups, respectively.
For the majority of outcome measures (i.e. changes
in headache days, pain and duration, including reduc-
tion in headache days, overall pain intensity, peak pain
intensity, headache-free days, days with prolonged and
severe headache and average headache duration), the
exploratory analyses showed no statistically significant
improvement over baseline when comparing the AS
group with the control groups (PS and MM), although
a numerical advantage appeared to be associated with
the AS group. Because the number of subjects in the
ancillary group was small, reliable comparisons could
not be made.
Responder rates
Figure 7 demonstrates responder rate across all four
groups. Responder rate is the percentage of subjects
who achieved a 50% or greater reduction in number
of headache days per month or a three-point or greater
reduction in average overall pain intensity compared
with baseline. The responder rate in the AS group
was 39%, compared with 6% in the PS group and
0% in the MM group. The differences between the
AS and the control groups were significant in explor-
atory analyses.
Disability and quality-of-life outcomes
The Profile of Moods States (POMS), MIDAS, SF-36,
functional disability and subject satisfaction scores
Table 3. Patient demographics and characteristics
Treatment group
Patient baseline characteristics
Adjustable
stimulation*
(N¼ 28)
Preset stimulation
(N¼ 16)
Medically managed
(control)
(N¼ 17)
Ancillary group
(N¼ 5)
Total
(N¼ 66)
Age (years, mean SD) 41 11.6 44 10.0 44 10.2 50 6.4 43 10.6
Gender ratio (F/M) 22/6 79%/21% 13/3 81%/19% 15/2 88%/12% 3/2 60%/40% 53/13 80%/20%
Headache history
Duration of migraine (years migraine
experienced prior to study entrance,
mean SD)
21 12.4 22 9.8 25 13.7 18 15.1 22 12.3
Disability scores (mean SD) 4.0 0.2 3.9 0.3 4.0 0.0 4.0 0.0 4.0 0.2
Number of headache days per
month (mean SD)
22.4 6.3 23.4 5.1 23.7 4.3 25.3 5.0 23.2 5.4
SD¼ standard deviation. F/M¼ female/male.
*Adjustable stimulation group: 29 subjects completed 3 months of treatment, but analysis includes only the 28 who completed 3 months assessment of
headache information in the electronic daily questionnaire.
Table 4. Percentage change in number of headache days
Mean SD
Treatment group N Baseline 3 months
Percentage change
from baseline
Adjustable stimulation 28 22.4 6.3 15.7 10.0 27.0 44.8
Preset stimulation 16 23.4 5.1 21.9 7.8 8.8 28.6
Medically managed 17 23.7 4.3 22.8 6.3 4.4 19.1
Ancillary 5 25.3 5.0 16.3 14.3 39.9 51.0
SD¼ standard deviation.
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were also evaluated in this study. Exploratory analyses
yielded significant differences between the AS and con-
trol groups in the measures reported here. The POMS
was used to measure six areas of mood states: tension-
anxiety, depression-dejection, anger-hostility, vigor-
activity, fatigue-inertia and confusion-bewilderment.
A lower score represents a decreased mood state.
Reductions in POMS scores from baseline to three
months were as follows: 8.7 12.0 for AS, 1.6 10.1
for MM and 0.4 9.4 for PS. Sixty-six percent of
subjects in the AS group and 25% of subjects in the
MM group reported satisfaction with treatment at
three months. Change from baseline in score on the
functional disability scale was 0.3 0.5 for the AS
group and 0.0 0.3 for the MM group. Change in
acute medication use was 1.6 7.6 in the AS group
and 0.6 5.0 in the MM group. Change in MIDAS
average grade was 0.4 0.8 for the AS group and
0.0 0.0 for the MM group, and change in MIDAS
headache pain score was 1.3 1.8 for the AS group
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and 0.0 0.9 for the MM group. Scores on the SF-36
Mental Health domain were 5.5 9.7 and 1.5 6.3
for the AS and MM groups, respectively.
For the majority of outcome measures of disability
and quality of life, including the functional disability
scale, MIDAS scores and SF-36, the exploratory
analyses showed no significant improvement over base-
line when comparing the AS group with the control
groups (PS and/or MM), although a numerical advan-
tage appeared to be associated with AS in most cases.
Because the number of subjects in the ancillary group
was small, reliable comparisons could not be made.
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Safety
Adverse device effects. A total of 53 subjects underwent
the implant procedure. Two subjects were intraopera-
tive failures, leaving 51 subjects who were successfully
implanted. Fifty-six ADEs occurred in 36 of the
51 subjects. Table 5 demonstrates the presence and fre-
quency of ADEs in the 51 subjects. Three subjects
experienced serious ADEs requiring hospitalization:
implant site infection, lead migration and postoperative
nausea. The most frequently reported ADE was lead
migration, which occurred in 12 of 51 subjects (24%).
There was no evidence of ADEs leading to long-term
complications or potential nerve damage. There were
no serious unanticipated ADEs reported or identified
in this study.
Non–device-related adverse events. Non–device-
related adverse events involved principally worsening
of migraine during the three-month testing period as
compared with baseline. Nine percent of the AS
group, 41% of the PS group and 24% of the MM
group reported increased migraine. Adverse events
related to medications were similar across treatment
groups and ranged from 6% to 18%. Table 6 presents
the non–device-related adverse events that were
reported in more than one subject. The ‘‘total’’ row
includes all events, including those reported in only
one subject.
Discussion
The data from this feasibility study suggest ONS for
medically intractable CM can be carried out relatively
safely and is worthy of further study for this indication.
Although the study was not prospectively powered
for efficacy evaluation, the 39% responder rate in the
AS group is comparable with response rates achieved
with widely used preventive CM treatments, such as
topiramate (16,17). Moreover, findings from the cur-
rent study are consistent with recent work suggesting
that the response to ONB may not predict treatment
outcomes of ONS in primary headache (18–20).
However, it is important to note that data from the
current study and others regarding the predictive
value of ONB must be interpreted with caution because
of their small sample sizes. The value of response to
ONB as a predictive factor remains to be determined,
with the results suggesting this issue needs resolving in
future studies.
The decision to employ ONS for the diagnosis of
CM rather than for occipital neuralgia is based on the
clinical phenotyping of patients responding to therapy
(7). This is not to eliminate headache of cervical origin
as a candidate for ONS; indeed, a retrospective review
of cases responding to the procedure demonstrated a
substantial cervicogenic cohort (21). Because CM is
among the most refractory and costly to treat of the
primary headache disorders and because chronic daily
or near-daily headache affects up to 4% of the public
(22), it was reasoned that if neurostimulation was effec-
tive and safe in treating this population, it would rep-
resent an important therapeutic contribution to quality
of life for those who suffer from this illness and perhaps
for long-term cost control as well.
Although the complete pathophysiology of CM
remains unclear, a role for the trigeminocervical
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complex seems established (23). The intermingling of
fibers from trigeminal afferents with those from cervical
inputs, especially those of C2, underpins the phenotype
of many primary headaches, including migraine (24).
It is clear from experimental studies even in nonhuman
primates (25) that second-order trigeminocervical
afferents are involved in dura-vascular nociceptive
transmission. Indeed, direct stimulation of C2 afferents
can excite second-order trigeminal afferents (26). Direct
evidence of this can be seen in patients with greater
stimulation of the occipital nerves (27) and, indeed,
from the distribution of pain, which ignores cutaneous
innervation boundaries. Moreover, clinical experience
whereby occipital nerve injections have been used in
the management of both migraine (28,29) and cluster
headache (30,31) reinforce the potential for treatment
of these disorders by manipulation of the nerve.
Functional imaging work has demonstrated changes
in thalamic activation with ONS in CM (7), without
change in the underlying brainstem activation (32),
suggesting a neuromodulatory mechanism for this
potential therapy.
This study indicates that the adverse events from the
period of implantation to three months are not prohib-
itive to further exploration of therapy. The primary
ADEs involved lead migration or dislodgement and
incision-site complications. Lead migrations, although
not generally defined as a serious adverse event,
ultimately require a repeat invasive procedure and
therefore should not be minimized in importance.
There was no evidence of ADEs leading to long-term
complications or potential nerve damage. Additional
studies are currently reviewing the long-term effects of
ONS. No unanticipated ADEs occurred in this study.
Moreover, from this study we have gained sufficient
technical information to move toward reducing lead
Table 5. Presence and frequency of device-related adverse events
Implanted subjects (N¼ 51)
Category Preferred term
No. of
events
No. of
subjects
Percentage
of subjects
Surgery/anesthesia Hypotension 1 1 2%
Incision site complication 4 4 8%
Post-procedural nausea 1 1 2%
Post-procedural pain 1 1 2%
Rash 1 1 2%
Stitch abscess 1 1 2%
Suture-related complication 1 1 2%
Programming Migraine 1 1 2%
Neck pain 1 1 2%
Therapeutic product ineffective 6 6 12%
Neurostimulator Neck pain 1 1 2%
Sensation of pressure 1 1 2%
Tenderness 1 1 2%
Neurostimulator pocket Discomfort 1 1 2%
Implant site hematoma 1 1 2%
Implant site infection 3 2 4%
Implant site irritation 1 1 2%
Implant site pain 2 2 4%
Lead High impedance 1 1 2%
Lead fracture 1 1 2%
Lead migration/dislodgment 12 12 24%
Therapeutic product ineffective 2 2 4%
Lead/extension tract Burning sensation 1 1 2%
Extension migration/dislodgment 1 1 2%
Implant site infection 8 7 14%
Implant site inflammation 1 1 2%
Total 56 36 71%
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migration in future studies, including considerations
of appropriate strain-relief loops, anchors, implant
locations, implant procedures and lead migration
assessment techniques.
Even if the design and power of this study were suf-
ficient to provide statistically reliable results, a respon-
der rate of 39%, or any of the other positive findings
reported here, might not seem compelling in support of
neurostimulation. Nonetheless, from the perspective of
an often treatment-refractory population of patients,
such a finding could represent an important therapeutic
signal for at least a subset of patients that justifies con-
tinued study in pursuit of ultimate therapeutic value.
Patients with CM are often left without effective treat-
ment, causing patients to lead lives that are painful and
compromised. Patients with CM often travel from phy-
sician to physician and center to center, and are pre-
scribed long lists of powerful medications, many in
complex combinations that both compromise function
and impose risk. Were a well-designed, controlled, and
blinded study to demonstrate that even a small subset
of patients with CM achieved reliable, substantial, pro-
longed benefit from ONS, we believe it would represent
an important contribution to the care of these patients.
This study had several limitations. First, trial dura-
tion was short. A longer period of observation might
reveal a different pattern of adverse events. Second,
complete patient and investigator blinding was difficult
to achieve. Although subjects and neurologists were
blinded, implanters were necessarily unblinded for con-
duct of the study. In addition, maintaining subjects in a
blinded mode is difficult in any study when stimulation
can be perceived. The PS group did not have a device
programmer, which also could have led to unblinding.
Third, the preset stimulation might have, itself, had a
therapeutic benefit, although this did not appear to be
the case in the current study. Finally, the parameter of
headache days could have used more sensitive defini-
tion, such as days with moderate or severe headache
specified by not only intensity but also duration.
Many questions beyond basic efficacy remain
unanswered for this therapy. Long-term safety of stim-
ulation, durability of any positive benefit and technical
and electronic reliability remain untested. Psychological
and clinical eligibility for stimulation, the effect of med-
ications on stimulation response (or lack thereof), inter-
ventional technique considerations and device and lead
design factors have yet to be determined or fully
explored.
There are many challenges to overcome before reli-
able conclusions on matters of efficacy and safety of
ONS in medically intractable CM can be established.
Table 6. Number of subjects with non–device-related adverse events, by study group*
Adjustable stimulation
(N¼ 33)
Preset stimulation
(N¼ 17)
Medically managed
(N¼ 17)
Ancillary
(N¼ 8)
Preferred term
No. of
subjects
Percentage
of subjects
No. of
subjects
Percentage
of subjects
No. of
subjects
Percentage
of subjects
No. of
subjects
Percentage
of subjects
Migraine 3 (9.1%) 7 (41.2%) 4 (23.5%) 0 (0.0%)
Drug toxicity 3 (9.1%) 2 (11.8%) 0 (0.0%) 1 (12.5%)
Headache 1 (3.0%) 2 (11.8%) 0 (0.0%) 1 (12.5%)
Adverse drug reaction 1 (3.0%) 1 (5.9%) 1 (5.9%) 0 (0.0%)
Sinusitis 0 (0.0%) 1 (5.9%) 1 (5.9%) 1 (12.5%)
Anxiety 1 (3.0%) 0 (0.0%) 1 (5.9%) 0 (0.0%)
Bronchitis 1 (3.0%) 1 (5.9%) 0 (0.0%) 0 (0.0%)
Depression 2 (6.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Dizziness 0 (0.0%) 1 (5.9%) 0 (0.0%) 1 (12.5%)
Fall 2 (6.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fungal infection 0 (0.0%) 2 (11.8%) 0 (0.0%) 0 (0.0%)
Hypothyroidism 0 (0.0%) 2 (11.8%) 0 (0.0%) 0 (0.0%)
Lymphadenopathy 1 (3.0%) 1 (5.9%) 0 (0.0%) 0 (0.0%)
Sinus headache 1 (3.0%) 0 (0.0%) 1 (5.9%) 0 (0.0%)
Upper respiratory
tract infection
0 (0.0%) 1 (5.9%) 1 (5.9%) 0 (0.0%)
Totaly 17 (52%) 13 (76%) 9 (53%) 6 (75%)
*Adverse events reported in more than one subject.
y‘‘Total’’ row includes all events, including those reported in only one subject.
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Developing a bona fide placebo group for surgical
implant studies is particularly important—and particu-
larly difficult. The perception of paresthesia may be
required to obtain pain control, but technical issues
make creation of this sensation in a placebo group a
major challenge for the design of randomized con-
trolled trials. Although the PS group represents a step
to address this issue, more must be done to assure that
the placebo stimulus is not itself therapeutically effec-
tive. In addition, better screening criteria are needed.
However, because medically intractable CM is a fre-
quent cause of disability and a therapeutic challenge
in neurological practice, attempting to overcome these
in future studies is a worthwhile pursuit.
Conclusion
On the basis of the current findings and in light of pre-
viously published work, we believe further investiga-
tional pursuit to evaluate the efficacy and safety of
ONS for medically intractable CM is justified.
Further study would be enhanced by improved stimu-
lator design, implanting technique and lead design and
by a well-targeted, carefully selected study population,
more robust endpoints, longer trial duration and
improved blinding techniques. Reliable conclusions
regarding efficacy cannot be established on the basis
of this study alone. Nonetheless, the results of this fea-
sibility study offer promise and should prompt further
study of ONS in medically intractable CM.
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